Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2010

Recordati Signs Up Esteve as Marketing Partner for Pitavastatin in Spain

  • Recordati and Esteve inked a co-marketing agreement for the dyslipidemia drug pitavastatin in Spain. Recordati has a European license to the therapy from Kowa Pharmaceuticals.

    Pitavastatin is an oral HMG-CoA reductase inhibitor. It is currently under review by U.K. regulatory authorities. Recordati says approval in the U.K. is expected during the second half of this year.

    The drug has been marketed in Japan since 2003 and was granted FDA sanction in August 2009. Called Livalo® in the U.S., FDA approval covers use of pitavastatin for the primary treatment of hypercholesterolemia and combined dyslipidemia.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »